Mpox infection is often followed by lingering physical symptoms
A study of adults diagnosed with mpox between May 2022 and January 2023 reveals that over half of the subjects diagnosed with mpox during the 2022 outbreak had… read more.
A study of adults diagnosed with mpox between May 2022 and January 2023 reveals that over half of the subjects diagnosed with mpox during the 2022 outbreak had… read more.
Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who received the injectable intramuscular antiviral medications cabotegravir and rilpivirine for nearly… read more.
Shionogi & Co. Ltd. announced that its group company, Shionogi China Co., Ltd, has received approval from the National Medical Products Administration (NMPA) of China for cefiderocol for… read more.
Most COVID-19 vaccine hesitancy is rooted in concerns that can be addressed and effectively reduced over time, according to a new study following more than 1.1 million people… read more.
Flu infections are rising sharply across the United States, contributing to at least 81,000 hospitalizations and 3,100 deaths so far this season, according to the U. S. Centers for… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Dovprela. (pretomanid). The marketing… read more.
Researchers report that once-weekly treatment with islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV has safely maintained high rates of virologic suppression through 48 weeks. The… read more.
Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250511 contains 31 recommendations and 10 good practice… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
NICE(UK): Cabotegravir is recommended as an option for pre-exposure prophylaxis (PrEP) alongside safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults and young… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for VacPertagen, a vaccine intended for prophylaxis against pertussis. The applicant… read more.
Shionogi & Co., Ltd. announced the launch of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%. Until now, Xofluza has only… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.